Skip to content

Disc Medicine IRON Total Equity

Total Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$20.07B+15.4%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$19.36B+17.4%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$655.47M-4.9%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$1.11B-24.4%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$1.16B+3.1%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$98.73M+201%

Other financials

Income statement

See full
Operating income-$69.5M-74.0%
Net income-$63.5M-86.3%
EPS (diluted)-$1.65-61.8%

Balance sheet

See full
Cash & equivalents$88.9M-27.5%
Total debt$31.1M+1.4%
Total assets$750.2M+5.8%

Cash flow

See full
Operating cash flow-$62.2M-50.4%
CapEx--100%
Free cash flow-$62.2M-47.4%

Valuation

See full
Market cap$2.69B+42.2%
Enterprise value$2.63B+46.7%

Returns & leverage

See full
Return on equity-35.8%+41.3pp
Debt / equity0.0×
Current ratio24×-13.6×

Where this comes from

Reported directly by Disc Medicine in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Disc Medicine's total equity?
Disc Medicine (IRON) reported total equity of $688.43M in Q1 2026.
How has Disc Medicine's total equity changed year-over-year?
Disc Medicine's total equity increased by 4.3% year-over-year, from $660.36M to $688.43M.
What is the long-term trend for Disc Medicine's total equity?
Over 5 years (2020 to 2025), Disc Medicine's total equity has grown at a 91.4% compound annual growth rate (CAGR), from -$28.81M to $739.83M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.